185 related articles for article (PubMed ID: 31122242)
1. Circulating miRNAs as non-invasive biomarkers to predict aggressive prostate cancer after radical prostatectomy.
Hoey C; Ahmed M; Fotouhi Ghiam A; Vesprini D; Huang X; Commisso K; Commisso A; Ray J; Fokas E; Loblaw DA; He HH; Liu SK
J Transl Med; 2019 May; 17(1):173. PubMed ID: 31122242
[TBL] [Abstract][Full Text] [Related]
2. Circulating microRNAs in plasma before and after radical prostatectomy.
McDonald AC; Raman JD; Shen J; Liao J; Pandya B; Vira MA
Urol Oncol; 2019 Nov; 37(11):814.e1-814.e7. PubMed ID: 31421994
[TBL] [Abstract][Full Text] [Related]
3. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
4. [Impact of Gleason score on biochemical recurrence free survival after radical prostatectomy with positive surgical margins].
Roux V; Eyraud R; Brureau L; Gourtaud G; Senechal C; Fofana M; Blanchet P
Prog Urol; 2017; 27(8-9):467-473. PubMed ID: 28576421
[TBL] [Abstract][Full Text] [Related]
5. A novel miRNA-based predictive model for biochemical failure following post-prostatectomy salvage radiation therapy.
Bell EH; Kirste S; Fleming JL; Stegmaier P; Drendel V; Mo X; Ling S; Fabian D; Manring I; Jilg CA; Schultze-Seemann W; McNulty M; Zynger DL; Martin D; White J; Werner M; Grosu AL; Chakravarti A
PLoS One; 2015; 10(3):e0118745. PubMed ID: 25760964
[TBL] [Abstract][Full Text] [Related]
6. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
7. Circulating miRNAs in localized/locally advanced prostate cancer patients after radical prostatectomy and radiotherapy.
Zedan AH; Hansen TF; Assenholt J; Madsen JS; Osther PJS
Prostate; 2019 Mar; 79(4):425-432. PubMed ID: 30537232
[TBL] [Abstract][Full Text] [Related]
8. Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy.
McDonald AC; Vira M; Walter V; Shen J; Raman JD; Sanda MG; Patil D; Taioli E
Prostate; 2019 Jun; 79(9):961-968. PubMed ID: 30958910
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of positive surgical margin and biochemical recurrence of patients treated with radical prostatectomy: a single-center 10-year report.
Li K; Li H; Yang Y; Ian LH; Pun WH; Ho SF
Chin Med J (Engl); 2011 Apr; 124(7):1001-5. PubMed ID: 21542957
[TBL] [Abstract][Full Text] [Related]
10. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.
Fossati N; Karnes RJ; Cozzarini C; Fiorino C; Gandaglia G; Joniau S; Boorjian SA; Goldner G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T; Briganti A
Eur Urol; 2016 Apr; 69(4):728-733. PubMed ID: 26497924
[TBL] [Abstract][Full Text] [Related]
11. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial.
Parker CC; Clarke NW; Cook AD; Kynaston HG; Petersen PM; Catton C; Cross W; Logue J; Parulekar W; Payne H; Persad R; Pickering H; Saad F; Anderson J; Bahl A; Bottomley D; Brasso K; Chahal R; Cooke PW; Eddy B; Gibbs S; Goh C; Gujral S; Heath C; Henderson A; Jaganathan R; Jakobsen H; James ND; Kanaga Sundaram S; Lees K; Lester J; Lindberg H; Money-Kyrle J; Morris S; O'Sullivan J; Ostler P; Owen L; Patel P; Pope A; Popert R; Raman R; Røder MA; Sayers I; Simms M; Wilson J; Zarkar A; Parmar MKB; Sydes MR
Lancet; 2020 Oct; 396(10260):1413-1421. PubMed ID: 33002429
[TBL] [Abstract][Full Text] [Related]
12. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
Kupelian PA; Katcher J; Levin HS; Klein EA
Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
[TBL] [Abstract][Full Text] [Related]
13. Circulating microRNA signature for the diagnosis of very high-risk prostate cancer.
Alhasan AH; Scott AW; Wu JJ; Feng G; Meeks JJ; Thaxton CS; Mirkin CA
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10655-60. PubMed ID: 27601638
[TBL] [Abstract][Full Text] [Related]
14. Proposed salvage treatment strategy for biochemical failure after radical prostatectomy in patients with prostate cancer: a retrospective study.
Miyake M; Tanaka N; Asakawa I; Morizawa Y; Anai S; Torimoto K; Aoki K; Yoneda T; Hasegawa M; Konishi N; Fujimoto K
Radiat Oncol; 2014 Oct; 9():208. PubMed ID: 25331298
[TBL] [Abstract][Full Text] [Related]
15. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
Cheng HH; Plets M; Li H; Higano CS; Tangen CM; Agarwal N; Vogelzang NJ; Hussain M; Thompson IM; Tewari M; Yu EY
Prostate; 2018 Feb; 78(2):121-127. PubMed ID: 29105802
[TBL] [Abstract][Full Text] [Related]
16. Circulating microRNA profiling for prediction of oncological outcomes in prostate cancer patients following radical prostatectomy.
Takamori H; Urabe F; Matsuzaki J; Kimura S; Sasaki H; Kimura T; Inaba K; Nakamura E; Matsui Y; Fujimoto H; Ochiya T
Prostate; 2022 Dec; 82(16):1537-1546. PubMed ID: 35971801
[TBL] [Abstract][Full Text] [Related]
17. Circulating miR-20a and miR-26a as Biomarkers in Prostate Cancer.
Mohammadi Torbati P; Asadi F; Fard-Esfahani P
Asian Pac J Cancer Prev; 2019 May; 20(5):1453-1456. PubMed ID: 31127907
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.
Kneebone A; Fraser-Browne C; Duchesne GM; Fisher R; Frydenberg M; Herschtal A; Williams SG; Brown C; Delprado W; Haworth A; Joseph DJ; Martin JM; Matthews JHL; Millar JL; Sidhom M; Spry N; Tang CI; Turner S; Wiltshire KL; Woo HH; Davis ID; Lim TS; Pearse M
Lancet Oncol; 2020 Oct; 21(10):1331-1340. PubMed ID: 33002437
[TBL] [Abstract][Full Text] [Related]
19. A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer.
Farran B; Dyson G; Craig D; Dombkowski A; Beebe-Dimmer JL; Powell IJ; Podgorski I; Heilbrun L; Bolton S; Bock CH
Carcinogenesis; 2018 Apr; 39(4):556-561. PubMed ID: 29471417
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer biochemical recurrence rates after robotic-assisted laparoscopic radical prostatectomy.
Ginzburg S; Nevers T; Staff I; Tortora J; Champagne A; Kesler SS; Laudone VP; Wagner JR
JSLS; 2012; 16(3):443-50. PubMed ID: 23318071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
